Login to Your Account

Genable Gets $6.8M for Gene Therapy in Retinitis Pigmentosa

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, November 16, 2011
DUBLIN, Ireland – Genable Technologies Ltd. raised €5 million (US$6.8) million in a Series B financing round to take forward a mutation-independent gene therapy approach for treating an autosomal-dominant form of retinitis pigmentosa (RP).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription